Business Standard

Dr Reddy's launches stomach, esophagus problems treatment drug in US

The product is a therapeutic equivalent generic version of Prevacid SoluTab delayed release orally disintegrating tablets approved by the US Food and Drug Administration (USFDA)

Dr Reddy's

In a regulatory filing, Dr Reddy''s laboratories announced launch of Lansoprazole DR (delayed release) orally disintegrating tablets.

Press Trust of India New Delhi

Drug major Dr Reddy's Laboratories on Monday said it has launched Lansoprazole delayed release orally disintegrating tablets, used to treat certain stomach and esophagus problems , in the US market.

The product is a therapeutic equivalent generic version of Prevacid SoluTab delayed release orally disintegrating tablets approved by the US Food and Drug Administration (USFDA).

In a regulatory filing, Dr Reddy's laboratories announced launch of Lansoprazole DR (delayed release) orally disintegrating tablets.

Quoting IQVIA Health data, Dr Reddy's said the Prevacid brand and generic had US sales of approximately USD 87 million for the most recent 12 months ending in December 2020.

 

Dr Reddy's Lansoprazole DR orally disintegrating tablets are available in 15 mg and 30 mg tablets in unit-dose packages of 100.

Shares of Dr Reddy's Laboratories were trading 1.50 per cent lower at Rs 4,615 apiece on BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Feb 22 2021 | 11:57 AM IST

Explore News